Street Calls of the Week
Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced Thursday that it has regained compliance with the minimum bid price requirement set by the Nasdaq Stock Market. The company received a letter from Nasdaq on September 18, 2025, confirming that it now meets the listing standard, which requires a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The stock, currently trading at $1.01, has shown strong momentum with a 37% price increase over the past six months, according to InvestingPro data.
Prelude Therapeutics had previously disclosed on March 28, 2025, that it was notified by Nasdaq on March 27, 2025, of its non-compliance with the minimum bid price requirement after its common stock failed to maintain a closing bid price of at least $1.00 per share. While the company maintains a strong balance sheet with more cash than debt, InvestingPro analysis indicates a WEAK overall financial health score, with analysts setting price targets ranging from $1 to $5.
According to the company’s statement in the SEC filing, Nasdaq notified Prelude Therapeutics that the matter is now closed. The company’s common stock continues to be listed on the Nasdaq Global Select Market under the symbol PRLD.
This information is based on a press release statement included in the company’s Form 8-K filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.